Goldman Sachs downgraded Dynavax to Sell, citing increased competition in the shingles vaccine market and uncertainty over hepatitis B revaccination demand.
Latest Ratings for DVAX
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 2021 | HC Wainwright & Co. | Maintains | Buy | |
| Aug 2021 | HC Wainwright & Co. | Maintains | Buy | |
| Aug 2021 | Goldman Sachs | Initiates Coverage On | Buy |
